Nexsen’s StrepSure® Faces Next Regulatory Steps Despite FDA Progress
Nexsen Limited has successfully completed a pivotal FDA Pre-Submission meeting for its StrepSure® diagnostic, significantly reducing regulatory risks and advancing its entry into the large US maternal health market.
- Positive FDA feedback on regulatory strategy and clinical validation
- De-risked pathway toward US market authorisation for StrepSure®
- StrepSure® offers rapid point-of-care testing for Group B Streptococcus
- Milestone validates Nexsen’s broader diagnostic platform
- Company progressing toward regulatory submission and commercial rollout
FDA Milestone Marks Key Regulatory Progress
Nexsen Limited (ASX:NXN) has announced a significant regulatory milestone with the successful completion of a Pre-Submission meeting under the U.S. Food and Drug Administration’s Q-Submission program. This meeting provided formal feedback on Nexsen’s lead diagnostic product, StrepSure®, a rapid test designed to detect Group B Streptococcus (GBS) in pregnant women. The positive FDA feedback affirms the company’s regulatory strategy, intended use, and clinical validation approach, effectively de-risking the pathway toward U.S. approval.
Addressing a Critical Maternal Health Need
Group B Streptococcus affects an estimated 18% of pregnant women globally and can lead to severe neonatal complications if undetected. Current testing methods rely on lab-based pathology with delays that limit timely treatment decisions during labour. StrepSure® offers a rapid, point-of-care solution delivering results within 20-30 minutes, enabling immediate clinical decisions without the need for laboratory infrastructure. With approximately 132 million births worldwide annually, the potential market for StrepSure® is substantial.
Strategic Validation and Commercial Implications
This FDA interaction not only validates Nexsen’s regulatory approach for StrepSure® but also serves as an early endorsement of its broader diagnostic platform aimed at rapid, point-of-care testing for time-critical conditions. The company is advancing key workstreams to support regulatory submission and commercial readiness, signalling confidence in its ability to bring StrepSure® to the world’s largest maternal health market. Nexsen’s Managing Director, Mark Muzzin, highlighted the milestone as a meaningful de-risking event that underscores the commercial potential of the product.
Looking Ahead
While StrepSure® remains investigational and has yet to receive regulatory approval for clinical use, this milestone marks a crucial step forward. Nexsen plans to provide further updates on regulatory progress and market rollout strategies in due course. The company’s broader pipeline, including diagnostics for kidney function and other health areas, stands to benefit from the regulatory insights gained through this process.
Bottom Line?
Nexsen’s FDA milestone sets the stage for a potential breakthrough in maternal health diagnostics, but the journey to market approval and commercial success continues.
Questions in the middle?
- What is the expected timeline for FDA approval following this Pre-Submission feedback?
- How will Nexsen position StrepSure® against existing GBS testing methods in the US market?
- What regulatory strategies will Nexsen apply to its broader diagnostic pipeline based on learnings from StrepSure®?
